Sulopenem Etzadroxil/Probenecid Drug Market Forecast and Analysis | Sulopenem Etzadroxil/Probenecid for uncomplicated Urinary Tract Infection: Market Size Analysis and Competitive Landscape by DelveInsight

(Albany, United States)//- The Sulopenem Etzadroxil/Probenecid market forecast report provides an analysis of the Sulopenem Etzadroxil/Probenecid market analysis and forecasts up to 2032 in the seven major markets (7MM). The comprehensive report provides an analysis of Sulopenem Etzadroxil/Probenecid market potential and Sulopenem Etzadroxil/Probenecid market share analysis in uncomplicated Urinary Tract Infection across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2019 to 2032.

The report also helps you to understand the Sulopenem Etzadroxil/Probenecid clinical and commercial landscape along with parameters like the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, special designations, and commercial and development activities.

Download Sample Report to know the https://www.delveinsight.com/report-store/sulopenem-etzadroxil-probenecid-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Sulopenem Etzadroxil/Probenecid Report Key Features and Coverage

The report presents a thorough description of Sulopenem Etzadroxil/Probenecid's characteristics and its use for uncomplicated Urinary Tract Infection, offering valuable insights into its drug's market potential. The report provides rich insights with respect to the competition in the market, as other emerging products that are in the advanced stage of pipeline development for uncomplicated Urinary Tract Infection are expected to give tough market competition to Sulopenem Etzadroxil/Probenecid. It is predicted that the launch of late-stage emerging therapies in the near future will significantly impact the uncomplicated Urinary Tract Infection market, and this report will help to understand how Sulopenem Etzadroxil/Probenecid is going to compete against other drugs.

Sulopenem Etzadroxil/Probenecid Drug Summary

Iterum Therapeutics is currently developing its inaugural compound, sulopenem, which is an innovative penem anti-infective substance available in both oral and intravenous (IV) formulations. Sulopenem has exhibited potent effectiveness in laboratory tests against a range of drug-resistant bacteria, including gram-negative, gram-positive, and anaerobic strains. This orally bioavailable compound is a broad-spectrum penem ß-lactam antibiotic, designed to combat infections caused by bacteria that are resistant to multiple drugs.

Originally discovered by Pfizer in the 1980s, sulopenem was initially formulated solely for IV administration. Extensive pre-clinical research and subsequent human trials were conducted by Iterum Therapeutics. Subsequently, an oral formulation of sulopenem was developed and subjected to Phase I and Phase II trials. Sulopenem, a parenteral thiopenem, displays broad antibacterial activity against a wide array of gram-positive and gram-negative bacteria, although it is not effective against Pseudomonas aeruginosa. Furthermore, it exhibits considerable stability against degradation by various beta-lactamases.

At present, Sulopenem is undergoing Phase I clinical investigation following the completion of a Phase III trial for the treatment of uncomplicated urinary tract infection (uUTI). The ongoing Phase I trial is a multi-center, open-label study aimed at evaluating the safety, tolerability, and pharmacokinetics of sulopenem, as well as Sulopenem Etzadroxil + Probenecid, in adolescent patients with bacterial infections, including uUTI. In November 2020, the company filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for oral sulopenem specifically for the treatment of uUTI in patients with a quinolone non-susceptible pathogen. However, the FDA has issued a Complete Response Letter (CRL), stating that additional data are required to support approval for the treatment of uUTI in adult women, and it cannot be approved in its current form.

Stay ahead of the competition by leveraging key insights and evolving trends in the Sulopenem Etzadroxil/Probenecid Market @ https://www.delveinsight.com/sample-request/sulopenem-etzadroxil-probenecid-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Why Sulopenem Etzadroxil/Probenecid Market Report?

Leading Sulopenem Etzadroxil/Probenecid for uncomplicated Urinary Tract Infection forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Sulopenem Etzadroxil/Probenecid
A thorough Sulopenem Etzadroxil/Probenecid market forecast will help understand how the drug is competing with other emerging Sulopenem Etzadroxil/Probenecid
Get an analysis of the Sulopenem Etzadroxil/Probenecid clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
The report also provides future market assessments for Sulopenem Etzadroxil/Probenecid market forecast analysis for uncomplicated Urinary Tract Infection in the 7 Major Markets, advanced qualitative analysis like SWOT, expert analysts' views, a detailed overview of market competitors, and a short analysis of other emerging therapies in uncomplicated Urinary Tract Infection.

Download the sample report to learn more about the evolving market dynamics @ https://www.delveinsight.com/sample-request/sulopenem-etzadroxil-probenecid-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related reports:

uncomplicated Urinary Tract Infection Market Report 2032

DelveInsight's "uncomplicated Urinary Tract Infection- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the uncomplicated Urinary Tract Infection, historical and forecasted epidemiology as well as the uncomplicated Urinary Tract Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

uncomplicated Urinary Tract Infection Pipeline 2023

"uncomplicated Urinary Tract Infection Pipeline Insights, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Onycholysis market. A detailed picture of the Onycholysis pipeline landscape is provided, which includes the disease overview and Onycholysis treatment guidelines.

uncomplicated Urinary Tract Infection Epidemiology 2032

DelveInsight's 'uncomplicated Urinary Tract Infection - Epidemiology Forecast-2032' report delivers an in-depth understanding of the uncomplicated Urinary Tract Infection, historical and forecasted epidemiology as well as the uncomplicated Urinary Tract Infection trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Leading Reports by DelveInsight:

Asthma Diagnostic Devices Market
Chronic Obstructive Pulmonary Disease Treatment Devices Market
Airway Management Devices Market
Cough Assist Devices Market
Pulse Oximeters Market
Hemodialysis Catheter Devices Market
Chronic Spontaneous Urticaria Market
Gender Dysphoria Market
Germany Healthcare Outlook
Biopsy Devices Pipeline Insight
Bacterial Conjunctivitis Market
Infliximab Biosimilar Insight
Eosinophilic Asthma Market
Cushing Syndrome Market
Functional Dyspepsia Market
Peripherally Inserted Central Catheters (PICC) Devices Market

Consulting Services:
DelveInsight's Healthcare Consulting Services offers a comprehensive and customized approach to address the diverse needs of clients in the healthcare sector. These services are specifically designed to tackle the most critical challenges faced by clients while also identifying and capitalizing on emerging opportunities.

By leveraging DelveInsight's deep industry knowledge, extensive market research capabilities, and advanced data analytics, healthcare consulting services provide clients with practical and data-driven solutions. The consultants collaborate closely with clients to gain a thorough understanding of their unique requirements and obstacles, enabling them to develop tailored strategies and solutions. DelveInsight's consulting expertise encompasses various aspects of the healthcare industry, including market access, commercial strategy, product development, and regulatory affairs.

Get in touch today to navigate the complexities of the life sciences industry and successfully achieve your business goals @ https://www.delveinsight.com/consulting

Contact Us:
Kritika Rehani
+91-9650213330
Email: info@delveinsight.com
https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.